Impact of Introducing the Pletaal Assist System on Drug Adherence in Outpatients with Ischaemic Stroke: A Pilot Study.
antiplatelet drug
electronic medication packaging
medication adherence
stroke
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
12
2020
accepted:
30
03
2021
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
29
4
2021
Statut:
epublish
Résumé
The effectiveness of Electronic Medication Packaging devices for monitoring drug adherence has been widely reported. However, conventional devices are expensive for routine use and cannot confirm whether the medication was administered. We aimed to determine, in a pilot and feasibility study, the impact of introducing a new medication support device, the Pletaal Assist System We assessed consecutive patients treated with cilostazol for >3 months at our stroke outpatient clinic from January 2018 to March 2020. The adherence rate was assessed as follows: (the number of pills prescribed minus the number of remaining pills)/the number of pills prescribed. We compared the adherence rates before, during, and after Pletaal Assist System Overall, 25 patients (median age, 68.5 years; range, 51-86 years; male, 64%) were enrolled. All participants were prescribed cilostazol (100 mg) twice a day. There was no significant difference in the adherence rate among the three periods. However, in 10 patients with adherence rate below 100%, the adherence rate during Pletaal Assist System Our preliminary evidence suggest that the Pletaal Assist System
Identifiants
pubmed: 33907385
doi: 10.2147/PPA.S297045
pii: 297045
pmc: PMC8064721
doi:
Types de publication
Journal Article
Langues
eng
Pagination
835-841Informations de copyright
© 2021 Oura et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Arch Intern Med. 1990 Sep;150(9):1881-4
pubmed: 2102668
JAMA. 2014 Sep 24;312(12):1237-47
pubmed: 25247520
Am J Health Promot. 2017 Jul;31(4):278-286
pubmed: 26730557
Am J Manag Care. 2015 Mar 01;21(3):e197-205
pubmed: 26014307
Encephale. 2002 May-Jun;28(3 Pt 1):266-72
pubmed: 12091789
N Engl J Med. 2005 Aug 4;353(5):487-97
pubmed: 16079372
Manag Care Interface. 1998 Sep;11(9):67-9, 75
pubmed: 10187590
Lancet Neurol. 2010 Oct;9(10):959-68
pubmed: 20833591
Stroke. 2010 Feb;41(2):397-401
pubmed: 20075360
Cochrane Database Syst Rev. 2014 Mar 26;(3):CD000029
pubmed: 24668137
Am J Hypertens. 1988 Jul;1(3 Pt 1):309-12
pubmed: 3291897
Clin Ther. 2001 Aug;23(8):1296-310
pubmed: 11558866
Medicine (Baltimore). 2019 Mar;98(12):e14872
pubmed: 30896633
Ann Pharmacother. 2002 Sep;36(9):1331-6
pubmed: 12196047
Arch Neurol. 2005 Aug;62(8):1217-20
pubmed: 16087761
AIDS. 2002 Jan 25;16(2):269-77
pubmed: 11807312
Hypertension. 1980 Nov-Dec;2(6):757-64
pubmed: 7007235
J Gen Intern Med. 2015 Jan;30(1):83-90
pubmed: 25361685
J Psychiatry Neurosci. 2001 Sep;26(4):325-9
pubmed: 11590972
Arch Neurol. 2010 Dec;67(12):1456-63
pubmed: 20697032
Patient Educ Couns. 1999 Jun;37(2):113-24
pubmed: 14528539
JAMA. 1989 Jun 9;261(22):3273-7
pubmed: 2716163
Arzneimittelforschung. 1985;35(7A):1144-9
pubmed: 4074426
Eur Heart J. 2013 Oct;34(38):2940-8
pubmed: 23907142
Am J Med. 2003 Jun 1;114(8):625-30
pubmed: 12798449
Br J Clin Pharmacol. 2016 Jul;82(1):268-79
pubmed: 27005306
Clin Pharmacol Ther. 1989 Aug;46(2):163-8
pubmed: 2758726
Am J Health Syst Pharm. 2001 Jun 15;58(12):1126-32
pubmed: 11449856
Arzneimittelforschung. 1985;35(7A):1189-92
pubmed: 4074432